| Literature DB >> 33480466 |
Brian I Shaw1, Hui-Jie Lee2, Cliburn Chan2, Robert Ettenger3, Paul Grimm4, Meghan Pearl3, Elaine F Reed5, Mark A Robien6, Minnie Sarwal7, Linda Stempora1, Barry Warshaw8, Congwen Zhao2, Olivia M Martinez9, Allan D Kirk1,10, Eileen T Chambers1,10.
Abstract
Depletional induction using antithymocyte globulin (ATG) reduces rates of acute rejection in adult kidney transplant recipients, yet little is known about its effects in children. Using a longitudinal cohort of 103 patients in the Immune Development in Pediatric Transplant (IMPACT) study, we compared T cell phenotypes after ATG or non-ATG induction. We examined the effects of ATG on the early clinical outcomes of alloimmune events (development of de novo donor specific antibody and/or biopsy proven rejection) and infection events (viremia/viral infections). Long-term patient and graft outcomes were examined using the Scientific Registry of Transplant Recipients. After ATG induction, although absolute counts of CD4 and CD8 T cells were lower, patients had higher percentages of CD4 and CD8 memory T cells with a concomitant decrease in frequency of naïve T cells compared to non-ATG induction. In adjusted and unadjusted models, ATG induction was associated with increased early event-free survival, with no difference in long-term patient or allograft survival. Decreased CD4+ naïve and increased CD4+ effector memory T cell frequencies were associated with improved clinical outcomes. Though immunologic parameters are drastically altered with ATG induction, long-term clinical benefits remain unclear in pediatric patients.Entities:
Keywords: clinical research/practice; immune regulation; immunosuppressant - polyclonal preparations: rabbit antithymocyte globulin; immunosuppression/immune modulation; kidney transplantation/nephrology; pediatrics; translational research/science
Mesh:
Substances:
Year: 2020 PMID: 33480466 PMCID: PMC7952017 DOI: 10.1111/ajt.16263
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086